New drug cocktail targets tough blood cancer
NCT ID NCT07460362
First seen Mar 10, 2026 · Last updated May 14, 2026 · Updated 4 times
Summary
This study tests a combination of two drugs, glofitamab and lenalidomide, in people with a fast-growing type of blood cancer called mantle cell lymphoma that has come back or not responded to prior treatments, including a BTK inhibitor. About 43 adults will receive the drugs intravenously and by mouth to see if the cancer shrinks or disappears. The goal is to find a better option for patients with limited choices.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, 100191, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.